Have a feature idea you'd love to see implemented?
Let us know!
VCNX Vaccinex Inc
Price (delayed)
$3.62
Market cap
$9.41M
P/E Ratio
0.49
Dividend/share
N/A
EPS
$7.37
Enterprise value
$6.56M
Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company's lead drug candidate, pepinemab, blocks SEMA4D,
Highlights
The quick ratio has soared by 152% from the previous quarter
Vaccinex's EPS has surged by 109% YoY
Vaccinex's revenue has plunged by 51% YoY but it has increased by 9% from the previous quarter
Vaccinex's gross profit has plunged by 51% YoY but it has increased by 9% from the previous quarter
Key stats
What are the main financial stats of VCNX
Market
Valuations
Earnings
Shares outstanding
2.6M
Market cap
$9.41M
Enterprise value
$6.56M
Price to earnings (P/E)
0.49
Price to book (P/B)
N/A
Price to sales (P/S)
18.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.92
Revenue
$388,000
EBIT
-$18.58M
EBITDA
-$18.47M
Free cash flow
-$15.87M
Per share
Balance sheet
Liquidity
EPS
$7.37
Free cash flow per share
-$7.83
Book value per share
-$0.76
Revenue per share
$0.19
TBVPS
$2.39
Total assets
$4.85M
Total liabilities
$6.18M
Debt
$59,000
Equity
-$1.32M
Working capital
-$1.42M
Debt to equity
-0.04
Current ratio
0.77
Quick ratio
0.63
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
-4,761.1%
Gross margin
100%
Net margin
-4,787.9%
Operating margin
-5,241.2%
Return on assets
-407.9%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-4,787.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VCNX stock price
How has the Vaccinex stock price performed over time
Intraday
0.56%
1 week
14.56%
1 month
30.69%
1 year
-71.41%
YTD
-61.12%
QTD
6.47%
Financial performance
How have Vaccinex's revenue and profit performed over time
Revenue
$388,000
Gross profit
$388,000
Operating income
-$20.34M
Net income
-$18.58M
Gross margin
100%
Net margin
-4,787.9%
The operating margin has plunged by 81% YoY but it has grown by 14% from the previous quarter
Vaccinex's net margin has plunged by 73% YoY but it has increased by 4% from the previous quarter
Vaccinex's revenue has plunged by 51% YoY but it has increased by 9% from the previous quarter
Vaccinex's gross profit has plunged by 51% YoY but it has increased by 9% from the previous quarter
Growth
What is Vaccinex's growth rate over time
Valuation
What is Vaccinex stock price valuation
P/E
0.49
P/B
N/A
P/S
18.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.92
Vaccinex's EPS has surged by 109% YoY
The company's equity has surged by 66% YoY and by 54% QoQ
VCNX's price to sales (P/S) is 89% less than its 5-year quarterly average of 170.5 and 45% less than its last 4 quarters average of 34.4
Vaccinex's revenue has plunged by 51% YoY but it has increased by 9% from the previous quarter
Efficiency
How efficient is Vaccinex business performance
Vaccinex's return on sales has shrunk by 73% YoY but it has increased by 4% QoQ
Vaccinex's ROA has increased by 14% YoY and by 9% from the previous quarter
Dividends
What is VCNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VCNX.
Financial health
How did Vaccinex financials performed over time
The total assets is 21% smaller than the total liabilities
The quick ratio has soared by 152% from the previous quarter
VCNX's current ratio has surged by 120% year-on-year and by 83% since the previous quarter
Vaccinex's debt is 104% more than its equity
Vaccinex's debt has plunged by 81% YoY and by 52% from the previous quarter
The company's equity has surged by 66% YoY and by 54% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.